NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 204)
Posted On: 11/02/2021 4:30:17 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules R&D Briefing to Release Breakthrough Research Findings
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be hosting an in-person and virtual research and development briefing. Scheduled for Nov. 8, 2021, from 8:30–9:30 a.m. EST, the briefing is slated to include breakthrough preclinical, research findings that indicate advancements in the company’s focus on creating a promising approach for patients in need of effective and safe prescription therapies in the mental health space. Cybin CEO Doug Drysdale and other key members of the company’s senior scientific research team will be hosting the event, which will be held during the Wonderland Conference in Miami; interested individuals can also attend the briefing virtually. In addition to Drysdale, presenters will include Cybin chief R&D officer Michael Palfreyman, head of R&D Geoff Varty and COO Aaron Bartlone. “We are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues,” said Cybin CEO Doug Drysdale in the press release. “At a time when COVID has exacerbated the mental health crisis to epidemic proportions, the Cybin team has been exceptionally productive. We are excited to share the deeply meaningful scientific progress that we have made. You will not want to miss this.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be hosting an in-person and virtual research and development briefing. Scheduled for Nov. 8, 2021, from 8:30–9:30 a.m. EST, the briefing is slated to include breakthrough preclinical, research findings that indicate advancements in the company’s focus on creating a promising approach for patients in need of effective and safe prescription therapies in the mental health space. Cybin CEO Doug Drysdale and other key members of the company’s senior scientific research team will be hosting the event, which will be held during the Wonderland Conference in Miami; interested individuals can also attend the briefing virtually. In addition to Drysdale, presenters will include Cybin chief R&D officer Michael Palfreyman, head of R&D Geoff Varty and COO Aaron Bartlone. “We are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues,” said Cybin CEO Doug Drysdale in the press release. “At a time when COVID has exacerbated the mental health crisis to epidemic proportions, the Cybin team has been exceptionally productive. We are excited to share the deeply meaningful scientific progress that we have made. You will not want to miss this.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼